Go Deep
Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 23,953 | 51.4 | 0.51 | 0.23 | 23.12 |
| Sep 2026 | 23,866 | 50.8 | 0.51 | 0.23 | 22.86 |
| Sep 2026 | 23,898 | 49.8 | 0.50 | 0.23 | 22.39 |
| Sep 2026 | 23,898 | 49.8 | 0.50 | 0.23 | 22.39 |
| Sep 2026 | 23,898 | 49.8 | 0.50 | 0.23 | 22.39 |
| Sep 2026 | 23,907 | 49.8 | 0.50 | 0.23 | 22.39 |
| Oct 2026 | 26,699 | 49.6 | 0.49 | 0.23 | 22.34 |
| Oct 2026 | 25,478 | 49.6 | 0.49 | 0.23 | 22.33 |
Balaxi Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 806,818,000.0 | 707,137,000.0 | 725,424,000.0 | 561,753,000.0 |
| Net Profit | 12,974,000.0 | 6,128,000.0 | 3,050,000.0 | 2,090,000.0 |
| EPS | 0.2 | 0.1 | 0.1 | 0.0 |
Balaxi Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 2,701,735,000.0 | 2,925,612,000.0 | 2,412,944,000.0 | 3,364,327,000.0 | — |
| Net Profit | 14,169,000.0 | 250,703,000.0 | -23,870,000.0 | 459,625,000.0 | — |
| EPS | 0.3 | 4.5 | -2.3 | 9.2 | — |
Balaxi Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 3,370,295,000.0 | 3,103,424,000.0 | 2,583,433,000.0 | 2,396,690,000.0 | — |
| Total Liabilities | 879,532,000.0 | 786,061,000.0 | 569,794,000.0 | 567,892,000.0 | — |
| Total Equity | 2,490,763,000.0 | 2,317,363,000.0 | 2,013,639,000.0 | 1,828,798,000.0 | — |
Owes vs Owns
Balaxi Pharmaceuticals Limited owed ₹0.26 for every ₹1 it owned in Mar 2026, up from ₹0.24 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.26× | 0.25× | 0.22× | 0.24× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Balaxi Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 4.3%Receivables 40.4%Inventory 24.8%Fixed assets (tangible) 14.3%Intangible assets 9.9%Other assets 6.3%
How it's funded — Mar 2026
Short-term debt 9.9%Long-term debt 6.6%Payables 6.3%Other liabilities 3.3%Shareholders' equity 73.9%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 14.6 | 39.4 | 62.3 | 28.2 |
| Receivables | 136.1 | 110.8 | 55.7 | 52.3 |
| Inventory | 83.5 | 78.5 | 82.2 | 105.0 |
| Fixed assets (tangible) | 48.4 | 35.7 | 16.3 | 18.1 |
| Intangible assets | 33.3 | 27.4 | 26.9 | 26.1 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 21.2 | 18.6 | 15.0 | 9.9 |
| Liabilities & equity | ||||
| Short-term debt | 33.4 | 30.4 | 17.7 | 10.8 |
| Long-term debt | 22.4 | 21.2 | 0.0 | 0.9 |
| Payables | 21.2 | 16.2 | 29.0 | 34.5 |
| Other liabilities | 11.0 | 10.8 | 10.3 | 10.6 |
| Shareholders' equity | 249.1 | 231.7 | 201.4 | 182.9 |
| Net tangible assets | 215.8 | 204.3 | 174.5 | 156.7 |
Balaxi Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -44,999,000.0 | -350,034,000.0 | 48,661,000.0 | 60,752,000.0 | — |
| Investing Activities | -207,794,000.0 | -217,638,000.0 | -10,463,000.0 | -105,654,000.0 | — |
| Financing Activities | 4,398,000.0 | 338,764,000.0 | 302,539,000.0 | 255,126,000.0 | — |